Prestige Consumer Healthcare (PBH) Projected to Post Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is anticipated to issue its Q2 2027 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $1.07 per share and revenue of $329.14 million for the quarter. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Investors may review the information on the company’s upcoming Q2 2027 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%. The firm had revenue of $265.71 million during the quarter, compared to analyst estimates of $253.02 million. During the same quarter in the previous year, the business earned $0.90 earnings per share. Prestige Consumer Healthcare’s quarterly revenue was up 6.5% on a year-over-year basis. On average, analysts expect Prestige Consumer Healthcare to post $4.56 EPS for the current fiscal year and $5.09 EPS for the next fiscal year.

Prestige Consumer Healthcare Price Performance

PBH opened at $49.78 on Tuesday. The company has a current ratio of 3.23, a quick ratio of 1.99 and a debt-to-equity ratio of 1.06. Prestige Consumer Healthcare has a 12-month low of $42.62 and a 12-month high of $71.07. The business’s fifty day simple moving average is $48.51 and its 200-day simple moving average is $54.12. The company has a market capitalization of $2.36 billion, a price-to-earnings ratio of 13.94, a PEG ratio of 1.50 and a beta of 0.34.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Zacks Research lowered shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 29th. Weiss Ratings reissued a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $67.67.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.